PREVIOUS
✖
Covishield Controversy
May 4 , 2024
14 days
147
0
- Controversy erupted when UK-based pharmaceutical giant AstraZeneca admitted that its Covid vaccine could cause blood clot-related side effects 'in very rare cases'.
- Its legal document mentioned that, this vaccine could cause Thrombosis with Thrombocytopenia Syndrome (TTS) in “very rare cases”.
- The very same vaccine was manufactured by the Serum Institute of India (SII) and was known in India as Covishield.
- TTS is a rare condition characterized by the formation of blood clots (thrombosis) accompanied by low platelet count (thrombocytopenia).
Leave a Reply
Your Comment is awaiting moderation.